China Biopharma Grants Cipla Exclusive License For TQB2102

China Biopharma's subsidiary Chia Tai Tianqing Pharmaceutical Group has signed an exclusive licensing and supply agreement with Cipla Limited for its self-developed TQB2102, according to ETNet. The company said it is entitled to upfront, potential development, regulatory and sales milestone payments of up to $123 million, plus double-digit royalties on annual net sales of TQB2102. This is the second regional licensing deal for TQB2102, and the two agreements have brought the group about $30 million in upfront and milestone payments so far. Under the deal, Cipla will have exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets. Cipla will handle local clinical development, registration filings and commercialisation in the licensed territories, while Chia Tai Tianqing will continue to manufacture and supply the drug. TQB2102 has received three breakthrough therapy designations from China's Center for Drug Evaluation, and is being advanced in multiple phase III studies covering HER2-low breast cancer, HER2-positive breast cancer, colorectal cancer and biliary tract cancer.